Pharmacogenomic data: FDA voluntary and required submission guidance

History and Evolution of Innovations in Clinical Pharmacology.

Clinical pharmacology and therapeutics·2025

Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2024

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin.

Cells·2023

Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.

Clinical and translational science·2022

Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.

CPT: pharmacometrics & systems pharmacology·2022

A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.

Clinical and translational science·2022

Current knowledge in pharmacogenomics and precision medicine: perspectives of the PGRN global PGx committee on improving drug therapies in underrepresented ethnic populations.

Pharmacogenomics·2026

U.S. student pharmacists perspectives on the pharmacogenomics of escitalopram and aripiprazole.

Pharmacogenomics·2026

Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan.

Pharmacogenomics·2026

Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis.

Pharmacogenomics·2026

Evaluation of dopamine transporter gene variations in Turkish children with attention deficit hyperactivity disorder treated with methylphenidate adverse effects.

Pharmacogenomics·2026

Polygenic risk score and risk of drug-induced liver injury after initiating antiretroviral therapy in people living with HIV.

Pharmacogenomics·2026

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Cureus·2026

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Frontiers in endocrinology·2026

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Canadian journal of kidney health and disease·2026

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Frontiers in pharmacology·2026

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Frontiers in molecular neuroscience·2026

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Therapeutic advances in neurological disorders·2026

Related Experiment Videos

Pharmacogenomic data: FDA voluntary and required submission guidance

Related Concept Videos

History and Evolution of Innovations in Clinical Pharmacology.

Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin.

Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.

Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.

A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.

Current knowledge in pharmacogenomics and precision medicine: perspectives of the PGRN global PGx committee on improving drug therapies in underrepresented ethnic populations.

U.S. student pharmacists perspectives on the pharmacogenomics of escitalopram and aripiprazole.

Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan.

Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis.

Evaluation of dopamine transporter gene variations in Turkish children with attention deficit hyperactivity disorder treated with methylphenidate adverse effects.

Polygenic risk score and risk of drug-induced liver injury after initiating antiretroviral therapy in people living with HIV.

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Related Experiment Videos

Pharmacogenomic data: FDA voluntary and required submission guidance

Related Concept Videos

Related Articles